The Study
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
This study is like a test where people who lost weight on a drug were randomly split into two groups: one kept getting the drug, the other got a fake injection. The group that kept getting the drug kept most of the weight off, while the other group regained a lot. This is strong proof that the drug helps maintain weight loss.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
People with obesity took tirzepatide for 36 weeks and lost about 21% of their body weight. Then some stayed on the drug and some got a dummy shot. After another year, those who stayed on tirzepatide lost even more weight (total 25%), while those who stopped regained a lot (only 9.9% total loss).
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 588 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1This is a big deal – it shows that tirzepatide is a chronic treatment like blood pressure pills; you can't just stop or the weight comes back.
- 289.5% of people who kept taking tirzepatide maintained at least 80% of their weight loss, compared to only 16.6% who stopped.
- 3On average, those who stopped regained 14% of their body weight, while those who continued lost another 5.5%.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
JAMA
Year
2023
Authors
L. Aronne, Naveed Sattar, Deborah B. Horn, H. Bays, Sean Wharton, Wen-Yuan Lin, N. Ahmad, Shuyu Zhang, Ran Liao, M. Bunck, I. Jouravskaya, Madhumita A. Murphy
Related Content
Claims (6)
In a clinical trial, people taking tirzepatide reported stomach-related side effects like diarrhea (10.7%), nausea (8.1%), and vomiting (5.7%). These side effects were usually mild or moderate, and only 1.8% of people stopped the medication because of them.
Tirzepatide reduces body weight by more than 20% in people who do not have diabetes.
In adults with obesity or overweight but not diabetes, taking tirzepatide for a full year after an initial 9-month treatment period results in an average additional weight loss of 5.5%, while stopping the drug and taking a placebo leads to an average weight regain of 14.0%. The difference between these groups is 19.4 percentage points, which is statistically significant.
Obesity or overweight adults who stop taking tirzepatide regain most of the lost weight. Only 10.5% of those who continue the drug maintain at least 80% of their weight loss after one year, while 83.4% of those who stop fail to maintain that level.
In a study lasting 88 weeks, adults with obesity or overweight who stayed on tirzepatide lost on average 25.3% of their starting weight, while those who switched to a placebo lost only 9.9%.
Tirzepatide treatment reduces belly fat and improves blood sugar, insulin, cholesterol, and blood pressure in overweight or obese adults without diabetes over 52 weeks, compared to placebo.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.